Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Background Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the surviva...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 March 2025
|
| In: |
Journal of the European Academy of Dermatology and Venereology
Year: 2025, Volume: 39, Issue: 11, Pages: 1975-1986 |
| ISSN: | 1468-3083 |
| DOI: | 10.1111/jdv.20650 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1111/jdv.20650 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.20650 
|
| Author Notes: | Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, Martin Kaatz, Ulrike Leiter, Bastian Schilling, Patrick Terheyden, Jessica Hassel, Michael Sachse, Jens Ulrich, Edgar Dippel, Frank Meiss, Claudia Pföhler, Alexander Kreuter, Rudolf Herbst, Michael Weichenthal, Lisa Zimmer, Friedegund Meier, Ricarda Rauschenberg, Peter Mohr, Fiona Brunnert, Imke von Wasielewski, Ralf Gutzmer, Dirk Schadendorf, Carola Berking, Selma Ugurel, Lucie Heinzerling |
| Summary: | Background Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti-PD1 therapy. Methods From the prospective multicentre real-world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 ± 4 weeks; n = 229) and no disease recurrence during therapy (A1) and patients with a premature end of treatment (<48 weeks; n = 214, B). Patients with disease recurrence during adjuvant treatment were included in cohort A2. Results The median duration of follow-up was 26.0 months [interquartile range (IQR) 18.0-34.0] in group A1 [median treatment duration 51.3 weeks (IQR 50.0-52.1) and 19.0 months (IQR 13.0-29.0)] in group B [median treatment duration 22.2 weeks (IQR 10.0-34.8)]. Reasons for early discontinuation were treatment-related side effects in 45.3% (n = 97) and other reasons than toxicity in 54.7% (n = 117). The 2-year rate of RFS was 72.4% (95% CI, 68.5-76.3) for patients in group B and 51.5% (95% CI, 48.8-54.2) in patients with regular and intended regular treatment duration (A1 plus A2). When analysing the patients who did not relapse during adjuvant treatment (A1), there was a significantly higher RFS rate of 84.1% (95% CI, 81.5-86.7). When only assessing patients with a recurrence after more than 12 months after initiation of therapy, there was a trend towards better RFS in patients with regular treatment duration. Conclusion In patients with resected metastatic melanoma, shorter treatment duration with anti-PD1 antibodies is not associated with a worse outcome. |
|---|---|
| Item Description: | Zuerst veröffentlicht: 22. März 2025 Gesehen am 08.10.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1468-3083 |
| DOI: | 10.1111/jdv.20650 |